Could a weight-loss drug ease long COVID fatigue? trial launches.
NCT ID NCT07128082
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study tests whether tirzepatide (Zepbound), a medicine used for diabetes and weight loss, can reduce Long COVID symptoms like fatigue. About 1000 adults with Long COVID will take either the drug or a placebo for 12 months. All tasks are done from home using surveys and wearable devices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scripps Research
La Jolla, California, 92037, United States
Conditions
Explore the condition pages connected to this study.